Myocardial Glucose Uptake Is Regulated by Nitric Oxide via Endothelial Nitric Oxide Synthase in Langendorff Mouse Heart

• Published in: Circulation research 2000-02, Vol.86 (3), p.270-274
• Main Authors: Tada, Hideo, Thompson, Carl I, Recchia, Fabio A, Loke, Kit E, Ochoa, Manuel, Smith, Carolyne J, Shesely, Edward G, Kaley, Gabor, Hintze, Thomas H
• Format: Article
• Language: English
• Subjects: Animals; Biological and medical sciences; Cyclic GMP - physiology; Fundamental and applied biological sciences. Psychology; Glucose - metabolism; Heart; In Vitro Techniques; Mice; Mice, Inbred C57BL; Mice, Knockout - genetics; Myocardium - metabolism; Nitric Oxide - physiology; Nitric Oxide Synthase - deficiency; Nitric Oxide Synthase - genetics; Nitric Oxide Synthase - physiology; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Reference Values; Vertebrates: cardiovascular system
• ISSN: 0009-7330; 1524-4571
• DOI: 10.1161/01.res.86.3.270

ABSTRACTAlthough the role of nitric oxide (NO) in the modulation of vascular tone has been studied and well understood, its potential role in the control of myocardial metabolism is only recently evident. Several lines of evidence indicate that NO regulates myocardial glucose metabolism; however, the details and mechanisms responsible are still unknown. The aim of this study was to further define the role of NO in the control of myocardial glucose metabolism and the nitric oxide synthase (NOS) isoform responsible using transgenic animals lacking endothelial NOS (ecNOS). In the present study, we examined the regulation of myocardial glucose uptake using isometrically contracting Langendorff-perfused hearts from normal mice (C57BL/6J), mice with defects in the expression of ecNOS [ecNOS (−/−)], and its heterozygote [ecNOS (+/−)], and wild-type mice [ecNOS (+/+)] (n=6, respectively). In hearts from normal mice, little myocardial glucose uptake was observed. This myocardial glucose uptake increased significantly in the presence of N-nitro-L-arginine methyl ester (L-NAME). Similarly, in the hearts from ecNOS (−/−), glucose uptake was much greater than in normal mice, whereas myocardial glucose uptake of ecNOS (+/−) and ecNOS (+/+) mice was not different from normal mice. In addition, myocardial glucose uptake of ecNOS (+/−) and ecNOS (+/+) mice increased significantly in the presence of L-NAME. At a workload of 800 g · beats/min, L-NAME increased glucose uptake from 0.1±0.1 to 3±0.4 μg/min · mg in ecNOS (+/−) mice and from 0.2±0.1 to 2.7±0.7 μg/min · mg in ecNOS (+/+) mice. Furthermore, in the hearts from ecNOS (−/−) mice, 8-bromoguanosine 3′:5′-cyclic monophosphate (8-Br-cGMP), a cGMP analog or S-nitroso-N-acetylpenicillamine (SNAP), a NO donor essentially shut off glucose uptake, and in hearts from ecNOS (+/−) mice, 1 H-[1,2,4]oxadiazolo[4,3,-a]quinoxalin-1-one (ODQ), an inhibitor of cGMP, increased the glucose uptake significantly. These results indicate clearly that cardiac NO production regulates myocardial glucose uptake via a cGMP-dependent mechanism and strongly suggest that ecNOS plays a pivotal role in this regulation. These findings may be important in the understanding of the pathogenesis of the diseases such as ischemic heart disease, heart failure, diabetes mellitus, hypertension, and hypercholesterolemia, in which NO synthesis is altered and substrate utilization by the heart changes.